Key result
Rivaroxaban reduces ischemic stroke risk ~21% vs. warfarin in obese non-valvular AF patients.
Why the study?
Anticoagulation is often required in patients with increased BMI, but clinical outcomes associated with rivaroxaban versus warfarin in obese patients with non-valvular AF required systematic comparison.
Does rivaroxaban reduce the risk of stroke, systemic embolism, and major bleeding compared to warfarin in obese patients with non-valvular atrial fibrillation?
Meta-Analysis (n=168,081)
Yes
Does rivaroxaban reduce the risk of stroke, systemic embolism, and major bleeding compared to warfarin in obese patients with non-valvular atrial fibrillation?
In this meta-analysis of 10 observational studies involving 168,081 obese patients with non-valvular AF, rivaroxaban was associated with significantly lower risks of ischemic stroke, hemorrhagic stroke, systemic embolism, and major bleeding compared to warfarin.
Answers are grounded in this paper and cite their sources.
May support rivaroxaban preference in obese non-valvular AF; leaves open confirmation by randomized trials.
Background Atrial fibrillation (AF) is an irregular heart rhythm which is becoming more and more common in this new era. Obesity is a risk factor for cardiovascular events, and obese patients are more at risk for stroke. The Framingham Heart Study demonstrated an increase in the developmental risk of AF by 4% for every unit (kg/m2) increase in body mass index (BMI). An anticoagulant is often required for the management of such patients. In this analysis, we aimed to systematically compare the clinical outcomes which were associated with rivaroxaban versus warfarin for the treatment of obese patients with non-valvular AF. Methods PubMed, EMBASE, Web of Science, http://www.ClinicalTrials.gov, Google Scholar, and Cochrane Central were the searched databases. Clinical outcomes including stroke, systemic embolism, and major bleeding were the endpoints. In this study, dichotomous data were analyzed by the RevMan software version 5.4. Risk ratio (RR) with 95% confidence interval (CI) was used for result interpretation. Results Ten studies consisting of a total number of 168,081 obese participants were included whereby 81,332 participants were treated with rivaroxaban and 86,749 participants were treated with warfarin. The risks of ischemic (RR: 0.79, 95% CI: 0.74–0.84; P = 0.00001) and hemorrhagic stroke (RR: 0.61, 95% CI: 0.48–0.76; P = 0.0001) as well as systemic embolism (RR: 0.73, 95% CI: 0.62–0.87; P = 0.0004) were significantly lower with rivaroxaban compared to warfarin for the management of these obese patients with non-valvular AF. Rivaroxaban was also associated with a significantly lower risk of major bleeding (RR: 0.75, 95% CI: 0.65–0.87; P = 0.0001). Conclusion Based on this analysis, rivaroxaban seemed to be a better option in comparison to warfarin, due to its association with significantly lower risks of stroke and bleeding outcomes in obese patients with non-valvular AF. However, this hypothesis should further be confirmed in larger clinical trials.
No takes yet. Share an insight, caveat, or question.
Zhuo et al. (2022) conducted a meta-analysis in Obese patients with non-valvular atrial fibrillation (n=168,081). Rivaroxaban vs. Warfarin was evaluated on Ischemic stroke (RR 0.79, 95% CI 0.74-0.84, p=0.00001). Rivaroxaban reduced the risk of ischemic stroke compared to warfarin in obese patients with non-valvular atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: